CURIS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.36 USD | -0.91% |
|
-0.61% | +27.53% |
| May. 07 | Curis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 07 | Transcript : Curis, Inc., Q1 2024 Earnings Call, May 07, 2024 |
Presentation Operator MessageOperator (Operator)Good morning and welcome to Curis' virtual KOL...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
Calendar
2024-05-21
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
16.51
USD
Average target price
79.8
USD
Spread / Average Target
+383.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +27.53% | 97.31M | |
| +19.36% | 47.02B | |
| +48.77% | 41.86B | |
| +0.22% | 41.76B | |
| -4.27% | 28.8B | |
| +11.85% | 26.05B | |
| -21.91% | 19.15B | |
| +4.02% | 12.55B | |
| +29.31% | 12.34B | |
| -3.86% | 11.82B |
- Stock Market
- Equities
- CRIS Stock
- News Curis, Inc.
- Transcript : Curis, Inc. - Special Call